![Jean François Soule-Susbielle](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ursprung des Netzwerks ersten Grades von Jean François Soule-Susbielle
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Subsidiary | Chemicals: Major Diversified | 7 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Jean François Soule-Susbielle
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Auriga Partners SA
![]() Auriga Partners SA Investment ManagersFinance Auriga Partners SA (Auriga) is an independent, management-owned venture capital firm which was founded by Patrick Bamas, Jacques Chatain and Bernard Daugeras in 1998. Headquartered in Paris, the firm's core activity is enterprise creation. In addition to providing a network of contacts capable of accelerating internationalization, and furthering strategic partnerships and business deals, Auriga manages several seed and early-stage funds specializing in information technology and life sciences. | Investment Managers | Director/Board Member | |
Molypharm
![]() Molypharm Pharmaceuticals: OtherHealth Technology Part of URGO Group SAS, Molypharm is a French company that manufactures elasticated medical dressings. The company is based in Veauche, France. Molypharm was acquired by Urgo Soins et Sante on September 01, 1997. | Pharmaceuticals: Other | Corporate Officer/Principal | |
VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member | |
Evolva SA
![]() Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
AlchiMedics SA
![]() AlchiMedics SA Chemicals: Major DiversifiedProcess Industries AlchiMedics SA specializes in coating technologies via electrografting. Its products enables covalent adhesion of nano to micrometric polymer-based layers on surfaces. The firm designs, develops and implements electro-grafting technology for implantable biomedical applications. The company was founded in 2007 and is headquartered in Grenoble, France. | Chemicals: Major Diversified | Director/Board Member | |
EVOLVA HOLDING SA | Food: Specialty/Candy | Director/Board Member | |
Isocell SA
![]() Isocell SA Food RetailRetail Trade Isocell SA operates as a holding company with interests in the manufacture of food supplements. It develops proprietary formulation for super-oxyde dismutase. The firm also targets food areas including sodas, sport drinks and dairies with wellness claims. It also engages in the ownership and operations of medical laboratories. The company was founded by Francois Vix on July 9, 2001 and is headquartered in Paris, France. | Food Retail | Director/Board Member |
Statistik
International
Frankreich | 7 |
Schweiz | 3 |
Sektoral
Health Technology | 4 |
Finance | 2 |
Commercial Services | 2 |
Process Industries | 2 |
Consumer Non-Durables | 2 |
Operativ
Director/Board Member | 8 |
Corporate Officer/Principal | 2 |
Private Equity Investor | 1 |
Independent Dir/Board Member | 1 |
Chairman | 1 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Jean François Soule-Susbielle
- Unternehmensverbindungen